Abbott’s study showed that during PCI, using OCT guidance compared to angiography enables physicians to achieve improved stent expansion. Credit: Michael We / Shutterstock.com.

Abbott has announced that its ILUMIEN IV OPTIMAL PCI (ILUMIEN IV) clinical study has demonstrated that intravascular imaging through optical coherence tomography (OCT) can enhance stent procedural outcomes, especially in complex cases.

Late-breaking data from the randomised global imaging study showed that during percutaneous coronary interventions (PCI), using OCT guidance compared to angiography enables physicians to achieve improved stent expansion, resulting in a greater minimal stent area (MSA).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Patients with medication-treated diabetes and complex artery disease were exclusively included in the study.

The study demonstrated that OCT guidance resulted in a statistically significant 7% rise in MSA compared to angiography guidance alone.

OCT guidance led to a 64% decrease in stent thrombosis (ST) rates, showing a significant statistical difference against angiographic guidance.

The study achieved its primary imaging endpoint of improving MSA.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, it failed to attain superiority in lowering the primary clinical endpoint, target vessel failure (TVF), which is a composite of cardiac death, myocardial infarction (MI) and target vessel revascularisation (TVR) at two years.

Abbott Vascular Business global medical affairs divisional vice-president and chief medical officer Nick West said: “The ILUMIEN IV data demonstrate the impact that OCT guidance can have when treating patients with complex coronary disease.

“In these cases, angiography alone simply cannot match the precision afforded by OCT to determine a treatment plan.”

The company’s latest OCT offering, Ultreon Software, is claimed to be the only intracoronary imaging solution on the market powered by artificial intelligence, guiding stents to place with precision.